Trial Profile
A Phase I/II Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Nov 2019
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Romidepsin (Primary)
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 10 Aug 2012 Actual end date (1 Jul 2008) added as reported by ClinicalTrials.gov.
- 15 Mar 2011 Company added in association field as reported by ClinicalTrials.gov.
- 15 Sep 2006 New trial record.